Wen leaving Invitae as CFO
Plus: Fenton succeeds CEO Requadt at Talaris, and an update from Sera
Genetic testing company Invitae Corp. (NYSE:NVTA) named Christine Gorjanc as interim CFO, effective July 1, following the resignation of CFO Yafei Wen who is leaving to pursue other opportunities. Gorjanc has served on the company’s board and as chair of the audit committee since November 2015.
Scott Requadt is leaving Talaris Therapeutics Inc. (NASDAQ:TALS) as CEO as part of a planned workforce reduction announced in April. The cell therapy company is considering strategic alternatives, including a possible business combination and divestiture of its cell therapy CMC capabilities. CFO Mary Fenton was named interim president and CEO...